Header Logo

Connection

James Mulshine to Gastrin-Releasing Peptide

This is a "connection" page, showing publications James Mulshine has written about Gastrin-Releasing Peptide.
Connection Strength

0.509
  1. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res. 1999 Nov; 5(11):3385-93.
    View in: PubMed
    Score: 0.171
  2. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest. 1996 Feb 01; 97(3):806-13.
    View in: PubMed
    Score: 0.033
  3. Scientific basis for cancer prevention. Intermediate cancer markers. Cancer. 1993 Aug 01; 72(3 Suppl):978-83.
    View in: PubMed
    Score: 0.028
  4. Effect of gastrin-releasing peptide on the pancreatic tumor cell line (Capan). Mol Carcinog. 1993; 8(4):214-20.
    View in: PubMed
    Score: 0.027
  5. Initiators and promoters of lung cancer. Chest. 1993 Jan; 103(1 Suppl):4S-11S.
    View in: PubMed
    Score: 0.027
  6. Prospective trial evaluating immunocytochemical-based sputum techniques for early lung cancer detection: assays for promotion factors in the bronchial lavage. J Cell Biochem Suppl. 1993; 17F:175-83.
    View in: PubMed
    Score: 0.027
  7. The correct dose: pharmacologically guided end point for anti-growth factor therapy. Cancer Res. 1992 May 01; 52(9 Suppl):2743s-2746s.
    View in: PubMed
    Score: 0.025
  8. Growth factors and other targets for rational application as intervention agents. Adv Exp Med Biol. 1992; 320:81-8.
    View in: PubMed
    Score: 0.025
  9. Preclinical evaluation of an anti-autocrine growth factor monoclonal antibody for treatment of patients with small-cell lung cancer. J Natl Cancer Inst. 1991 Oct 16; 83(20):1470-6.
    View in: PubMed
    Score: 0.024
  10. Autocrine growth factors as therapeutic targets in lung cancer. Chest. 1989 Jul; 96(1 Suppl):31S-34S.
    View in: PubMed
    Score: 0.021
  11. In vivo diagnosis and therapy of human tumors with monoclonal antibodies: selection of antibodies and preliminary clinical studies in small cell carcinoma of the lung. Int J Rad Appl Instrum B. 1989; 16(2):159-62.
    View in: PubMed
    Score: 0.020
  12. Solid-phase peptide quantitation assay using labeled monoclonal antibody and glutaraldehyde fixation. Anal Biochem. 1988 Oct; 174(1):224-34.
    View in: PubMed
    Score: 0.020
  13. Clinical use of a monoclonal antibody to bombesin-like peptide in patients with lung cancer. Ann N Y Acad Sci. 1988; 547:360-72.
    View in: PubMed
    Score: 0.019
  14. Consideration of the chemistry of solid-phase matrix interaction leads to improved quantitation of neuropeptides. Ann N Y Acad Sci. 1988; 547:41-53.
    View in: PubMed
    Score: 0.019
  15. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest. 1997 Jul; 112(1):256-61.
    View in: PubMed
    Score: 0.009
  16. [Psi 13,14] bombesin analogues inhibit growth of small cell lung cancerin vitro and in vivo. Cancer Res. 1991 Apr 01; 51(7):1798-802.
    View in: PubMed
    Score: 0.006
  17. A novel bombesin receptor antagonist inhibits autocrine signals in a small cell lung carcinoma cell line. Biochem Biophys Res Commun. 1988 Nov 15; 156(3):1383-9.
    View in: PubMed
    Score: 0.005
  18. Gastrin-releasing peptide and other autocrine growth factors in lung cancer: pathogenetic and treatment implications. Important Adv Oncol. 1988; 55-64.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.